A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

NCT03846310 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer
Nonsquamous Nonsmall Cell Neoplasm of Lung
Sensitizing EGFR Gene Mutation

Interventions

DRUG: Etrumadenant
DRUG: Zimberelimab
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Pembrolizumab

Sponsor

Arcus Biosciences, Inc.

Collaborators

[object Object]